MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202521006565 A) filed by Dr. Meghnad Ganesh Joshi; and Dr. Vishwanath Vithal Bhosale on January 27, 2025, for "formulation And Synthesis Process Of Mucosal Connective Tissue Loaded Gel-Based Topical Agent For Diabetic Wound Hearing Applications''.
Inventors include Dr. Meghnad Ganesh Joshi; Mr. Ankit Satish Kamble; Miss. Mrunal Narendra Damle; Mr. Omkar Rajendra Sonkawade; and Dr. Vaishali Vinayak Gaikwad.
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: Abstract: The present invention relates to a novel gel-based topical composition comprising Wharton's jcny iOi* trie promotion Oi woiuiu ixc&iing, spccuicmiy targeting uiaoctic wounus anu reiateu complications. Wharton's Jelly, a mucosal connective tissue conventionally regarded as biological waste, is employed as a key component due to its regenerative potential. The composition includes growth factors such as Insulin-like Growth Factor (IGF), Epidermal Growth Factor (EGF), Transforming Growth Factor-alpha (TGF-a), and Platelet-Derived Growth Factor (PDGF), which synergistically enhance cellular regeneration and expedite wound healing processes in hyperglycemic conditions. Furthermore, the topical gel is vmiwi^u vviui gij vuoaiimiugiy wtuia yvjrvvjoy, g,ij wi/pii/iwino, iij cu ui wiuw ttwiu, cuiu Wi.11/11u.j.1r1.tin sulfate, providing additional structural and functional support for tissue repair. This invention is designed to mitigate the adverse effects of impaired regenerative capacity often observed in diabetic patients, including wound progression, gangrene, necrosis, and the risk of amputation. The unique formulation offers a biocompatible, biologically active treatment method, thereby presenting a significant advancement in the therapeutic management of diabetic wounds.
Disclaimer: Curated by HT Syndication.
